The reading WAidid suggests this week in an article signed by WAidid board member, professor Kathryn Edwards, and Jesse M. Hackell and published by the American Academy of Pediatrics, "Countering Vaccine Hesitancy".
Immunizations have led to a significant decrease in rates of vaccine-preventable diseases and have made a significant impact on the health of children. However, some parents express concerns about vaccine safety and the necessity of vaccines. The concerns of parents range from hesitancy about some immunizations to refusal of all vaccines. Vaccine discussions continue to occupy the media and Internet, and every parent of a child for whom vaccination is recommended is exposed to these messages on a regular basis. Data have shown that participation in social media reinforces one's beliefs about vaccination, no matter what those beliefs are. The pediatrician is often the only medically trained person available to discuss vaccine matters with parents, and it is incumbent on him or her to provide scientifically based and balanced information when these questions are asked. Countering vaccine hesitancy can best be accomplished in the course of clinical practice through open communication and discussion between the pediatrician and the parents.
Click here to have access to the article.
This week WAidid suggests a recent study from The New England Journal of Medicine (07/21/16) that tried to identify the immune responses induced by a multicomponent meningococcal serogroup B vaccine
In the United States, meningococcal disease, caused primarily by Neisseria meningitidis serogroups B, C, and Y, presents a substantial threat to public health. The prevention of serogroup B disease has presented particular challenges. Between 2009 and 2015, seven meningococcal B outbreaks occurred at U.S. Universities. No meningococcal B vaccine was licensed in the United States at that time, although the multicomponent meningococcal serogroup B (4CMenB) vaccine, Bexsero, was licensed elsewhere.
The vaccine was offered to nearly 6000 students, beginning in December 2013. Within 6 months, 95% of eligible students had received at least one dose and 89% had completed the two-dose series.
The authors conducted a seroprevalence survey among students to assess vaccination status and collect serum specimens to quantify titers of serum bactericidal antibodies (SBA) with an assay that included human complement (hSBA). They compared the proportion of vaccinated and unvaccinated participants who were seropositive for the outbreak strain and for one closely related reference strain (44/76-SL, which included fHbp) and one mismatched reference strain (5/99, which included neisserial adhesin A), both of which were used in vaccine development. Seropositivity was defined as an hSBA titer of 4 or higher.
Eight weeks after the second dose of the 4CMenB vaccine was administered, there was no evidence of an hSBA response against the outbreak strain in 33.9% of vaccines, although no cases of meningococcal disease caused by N. meningitidis B were reported among vaccinated students.
AUTHORS: Nicole E. Basta, Adel A.F. Mahmoud, Julian Wolfson, Alexander Ploss, Brigitte L. Heller, Sarah Hanna, Peter Johnsen, Robin Izzo, Bryan T. Grenfell, Jamie Findlow, Xilian Bai, Ray Borrow.
To read the abrstract online click HERE